A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases. Lee J, Ahn MJ. J Thorac Oncol 2021;16:e14.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lee J, Ahn MJ. A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases. J Thorac Oncol 2021;16:e14.
PMID: 33494929